ProCE Banner Activity

Phase I/II KOMET-001: First-in-Human Study of Ziftomenib, a Novel KMT2A-Menin Inhibitor, in Relapsed/Refractory AML

Slideset Download
Conference Coverage

Current phase Ia/Ib analysis reports manageable safety and preliminary efficacy with ziftomenib in patients with relapsed/refractory AML, with a CR rate of 30% in 20 patients with NPM1-mutated disease.

Released: December 12, 2022

Expiration: December 11, 2023

No longer available for credit.
Begin Activity

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

AbbVie

Amgen

AstraZeneca

Epizyme

GSK

Incyte Corporation

Jazz Pharmaceuticals

Karyopharm Therapeutics Inc.

Novartis Pharmaceuticals Corporation

Sanofi

Seagen